Coenzyme Q10 (Ubiquinone)

Coenzyme Q10 (CoQ10) is a lipid-soluble antioxidant that could have beneficial effects in patients undergoing cardiac surgery with cardiopulmonary bypass. There is no clear evidence about its clinical effects or a systematic review published yet. We aimed to conduct a systematic review and meta-analysis of the literature to elucidate the role of coenzyme Q10 in preventing complications in patients undergoing cardiac surgery with cardiopulmonary bypass. We searched the PubMed Database using the following keywords: Coenzyme Q10, ubiquinone, ubiquinol, CoQ10, Heart Surgery, Cardiac surgery. Articles were systematically retrieved, selected, assessed and summarized for this review. We performed separate meta-analyses for different outcomes (inotropic drug requirements after surgery, incidence of ventricular arrhythmias and atrial fibrillation, cardiac index 24 h after surgery and hospital stay), estimating pooled odds ratios (ORs) or mean differences of the association of CoQ10 administration with the risk of these outcomes. Eight clinical trials met our inclusion criteria. Patients with CoQ10 treatment were significantly less likely to require inotropic drugs after surgery {OR [95% confidence interval (CI) 0.47 (0.27-0.81)]}, and to develop ventricular arrhythmias after surgery [OR (95% CI) 0.05 (0.01-0.31)]. However, CoQ10 treatment was not associated with Cardiac index 24 h after surgery [mean difference (95% CI) 0.06 (-0.30 to 0.43)], hospital stay (days) [mean difference (95% CI) -0.61 (-4.61 to 3.39)] and incidence of atrial fibrillation [OR (95% CI) 1.06 (0.19-6.04)]. Since none of the clinical trials included in this review report any adverse effects associated to CoQ10 administration, and coenzyme Q10 has been demonstrated to be safe even at much higher doses in other studies, we conclude that CoQ10 should be considered as a prophylactic treatment for preventing complications in patients undergoing cardiac surgery with cardiopulmonary bypass. However, better quality randomized, controlled trials are needed to clarify the role of CoQ10 in patients undergoing cardiac surgery with cardiopulmonary bypass. © The Author 2014. Published by Oxford University Press

Background/Objectives: Oxidative stress plays an important role in the pathophysiology of endometriosis, contributing to inflammation, immune dysregulation, and lesion progression. This has led to growing interest in antioxidant-based strategies as potential supportive interventions. Methods: A literature search was conducted using PubMed, Scopus, and Web of Science databases, covering studies published from database inception until the end of January 2026. The review focused on clinically relevant endpoints, including pain intensity, markers of inflammation and oxidative stress, reproductive parameters, and quality of life. Results: Among the analyzed interventions, the most consistent clinical effects were observed with melatonin, with randomized controlled trials indicating a moderate reduction in pain. N-acetylcysteine shows potentially beneficial effects; however, the available clinical data remain limited and heterogeneous. For other supplements, the evidence is inconsistent or insufficient to support clear clinical conclusions, and in many cases relies on indirect or mechanistic findings rather than well-established clinical outcomes. Conclusions: Current evidence does not support the use of non-mineral antioxidant supplements as standalone therapy for endometriosis. They may be considered as adjunctive strategies, although their clinical effectiveness remains uncertain and requires confirmation in well-designed randomized clinical trials.

BACKGROUND: Several meta-analyses suggest that Coenzyme Q10 (CoQ10) supplementation is associated with glycemic control; however, findings about fasting blood glucose (FBG) and haemoglobin A1c (HbA1c) remain inconsistent across studies. Accordingly, this study aimed to synthesise the results to present a firm conclusion in relation to the efficacy of CoQ10 on glycemic control. METHODS: A systematic search was conducted to find meta-analyses of randomised controlled trials using PubMed, Scopus, Web of Science and the Cochrane Database of Systematic Reviews from inception to March 6, 2025. Also, the methodological quality of included studies was evaluated using the AMSTAR2 tool. RESULTS: In total, eight meta-analyses were included in this umbrella systematic review and meta-analysis. Pooled analysis using standardized mean difference analysis demonstrated that CoQ10 is associated with decreased FBG. While it didn't exert any significant changes on the HbA1c, HOMA-IR, and insulin levels. In addition, the combined effect of CoQ10 using weighted mean difference analysis revealed that CoQ10 is able to decrease the FBG (5.04 mg/dL), HbA1c (0.17%), HOMA-IR (0.72), and insulin (1.32 μIU/mL) levels significantly. CONCLUSION: The present study suggests that CoQ10 supplementation may have a moderate beneficial effect on glycemic control in diabetic patients, though findings differ depending on analytic approach. © 2026 The Author(s). Endocrinology, Diabetes & Metabolism published by John Wiley & Sons Ltd.

Coenzyme Q10 (CoQ10) is a naturally occurring biochemical cofactor found in all human cell membranes in two interconvertible forms: oxidized ubiquinone and reduced ubiquinol. Clinical studies indicate that different CoQ10 formulations have different absorption rates, highlighting research comparing their systemic bioavailability. This study compared the oral bioavailability of cocrystal formulation soft gels (test product), a novel ubiquinol formulation, and ubiquinone formulation (reference product) in a randomized, double-blind, two-period crossover study with 12 healthy subjects under fasting conditions. The secondary objective of this study was to evaluate the safety and tolerability of the ubiquinol formulation. The pharmacokinetic analyses indicated that the test ubiquinol formulation demonstrated substantially higher relative systemic bioavailability compared with the ubiquinone reference. The geometric mean ratios (test/reference) for baseline-corrected peak plasma concentration (Cmax) and area under the curve from zero to last quantifiable time (AUC0-t) were 2.20 and 2.01, respectively, with 90% confidence intervals of 1.59-3.04 and 1.51-2.70. The geometric mean ratio for AUC from time zero to infinity (AUC0-∞) was 3.43 (90% CI: 1.47-8.00). No adverse events were reported in this small pilot study for either of the formulations. These findings demonstrate that ubiquinol has a better systemic bioavailability than ubiquinone, supporting the novel formulation's potential as a promising alternative to traditional CoQ10 supplements. © 2026 Credevo Pte. Ltd. Cocrystal Health Industry Co., Ltd and The Author(s). Clinical Pharmacology in Drug Development published by Wiley Periodicals LLC on behalf of American College of Clinical Pharmacology.

Declines in physical function with advancing age increase the risk of functional limitations and chronic disease. Excess mitochondrial reactive oxygen species (mitoROS)-related oxidative stress is linked to physical dysfunction with ageing, but the effects of therapies targeting excess mitoROS on age-associated physical dysfunction are unclear. Here, we determined the efficacy of the mitochondria-targeted antioxidant MitoQ for improving multiple domains of physical function, first in old mice and then in high-functioning older adults in a randomized, placebo-controlled, cross-over design clinical trial. In old male C57BL6/N mice (N = 22-26; 27 months), we found that 4 weeks of treatment with MitoQ (250 µm in the drinking water) attenuated the age-related decline in grip strength, co-ordination, and endurance without effects in young mice (N = 18-20; 6 months). The effects of MitoQ in old mice were accompanied by lower levels of skeletal muscle mitochondria-specific superoxide production and markers of mitoROS-related oxidative stress (i.e. phosphorylated SHC adaptor protein 1, isoform p66) and inflammation (i.e. interleukin-6, tumour necrosis factor-alpha, interferon-gamma). In the clinical trial, we did not observe convincing effects of 6 weeks of MitoQ (20 mg day-1) treatment on physical function in healthy older adults (N = 18; aged 60-79 years). However, exploratory subgroup analyses suggest possible effects of MitoQ on peak leg extension power and grip strength in participants ≥70 years of age. Our findings provide preclinical, proof-of-concept evidence for targeting excess mitoROS with MitoQ to reverse physical dysfunction with ageing. Although the effects of MitoQ did not directly translate to high functioning older adults, our initial observations suggest MitoQ may have greater efficacy in older, more physically frail individuals. KEY POINTS: Excess mitochondrial reactive oxygen species (mitoROS)-related oxidative stress is linked to physical dysfunction with ageing, but the effects of therapies targeting excess mitoROS on age-associated physical dysfunction are unclear. In old mice, chronic supplementation with the mitochondria-targeted antioxidant Mito

ObjectiveThis study aimed to investigate whether coenzyme Q10 is effective in preventing exercise-induced oxidative stress and muscle damage.MethodsFourteen randomized controlled studies examining the effects of supplementation with coenzyme Q10 analogs on postexercise oxidative stress and muscle damage were identified through searches in literature databases, including PubMed, the Cochrane Library, Embase, and Web of Science, and then the quality of the included studies was assessed. Quantitative and qualitative analyses were performed.ResultsThe study screened 14 randomized controlled trials that included a total of 433 subjects. The results demonstrated that oral coenzyme Q10 elevated blood coenzyme Q10 concentration (standardized mean difference: 2.710, 95% confidence interval: 1.57-3.85, p < 0.00001) and reduced blood malondialdehyde concentration (standardized mean difference: -0.289, 95% confidence interval: -0.541 to -0.038, p = 0.024). Additionally, oral coenzyme Q10 was found to reduce blood creatine kinase values (standardized mean difference: -1.532, 95% confidence interval: -2.856 to -0.209, p = 0.023), suggesting a potential protective effect on skeletal muscle. The metabolism-related blood lactate and maximal oxygen uptake levels were not affected by coenzyme Q10 (standardized mean difference: -0.68, 95% confidence interval: -1.89 to 0.53, p = 0.271; standardized mean difference: -0.156, 95% confidence interval: -0.79 to 0.478, p = 0.630).ConclusionsCoenzyme Q10 may reduce exercise-induced oxidative stress on blood malondialdehyde and exert a protective effect on muscle; however, no effect was observed from the anaerobic and aerobic metabolism of the organism.

Objectives: This study investigated whether CoQ10 supplementation enhances physical adaptations to high-intensity interval training (HIIT) in muscular strength, power, and physical function in older adults. Method: In a double-blind, randomized controlled trial, 38 adults aged 65-75 were assigned to either a CoQ10 (Females: 8; Males: 11) or placebo (Females: 8; Males: 11) group and completed an 8-week supervised HIIT program. Lower- and upper-body strength (30s 5-repetition chair stand [5XSST], chair standing [30CST], handgrip strength [HGR/L]), balance (single-leg stand [SLS], timed up and go [TUG]), mobility (25-foot walk [25FW]), and aerobic endurance (6-minute walk [6MWT]) were assessed pre- and post-intervention. Results: The CoQ10 group demonstrated significantly greater improvements in 5XSST and 30CST compared to the placebo group (p < 0.05). Both groups showed significant within-group improvements in right and left handgrip strength, SLS, 6MWT, and TUG (all p < 0.001), with no significant between-group differences observed for these outcomes (p > 0.05). No adverse events were reported. Conclusion: While CoQ10 supplementation enhanced improvements in lower-body strength and power, as indicated by the greater gains in 5XSST and 30CST performance compared to the placebo, no between-group differences were observed in TUG, grip strength, or other functional outcomes. This suggests that the performance-related effects of CoQ10 may be more specific to muscular power output and fatigue resistance, rather than general mobility or balance-related tasks. These findings highlight the potential of CoQ10 as a targeted adjunct in exercise for supporting lower-body function and physical performance in older adults.

BACKGROUND: Coenzyme Q10 (CoQ10), a vital mitochondrial antioxidant, may enhance cardiovascular recovery and delay fatigue in athletes. This double-blind, randomized, placebo-controlled trial investigated CoQ10's effects on cardiac stress markers and exercise performance in 16 professional soccer players. METHODS: Participants received either CoQ10 (n = 8) or placebo (n = 8) for 30 days and completed exhaustive aerobic cycling tests pre- and post-supplementation. Blood samples were collected at six time points to analyze GDF-15, NT-proBNP, and hs-TnT levels. RESULTS: In the CoQ10 group, GDF-15 rose post-exercise (PreEx1-PostEx1: +8.84%, p = 0.003; PreEx2-PostEx2: +5.37%, p = 0.001) but declined by 24 h post-Ex1 (- 5.28%, p = 0.003) and 24 h post-Ex2 (-6.62%, p = 0.001) compared to post-Ex1 & post-Ex2, respectively. NT-proBNP increased post-Ex1 (19.66%, p = 0.001), post-Ex2 (12.09%, p = 0.001) but decreased in 24 h-Ex1 (- 20.28%, p = 0.001), 24 h-Ex2 (-20.83%, p = 0.001) compared to post-Ex1&Ex2, respectively. Following a 31.18% increase post-Ex1, a smaller 23.65% increase was observed post-Ex2 in hs-TnT levels, however, decreases of -19.57 and - 32.20% were observed 24 h- postEx1&Ex2 compared to post-Ex1&Ex2, (p = 0.001 for all). Time to fatigue (TTF) improved post-supplementation (- 0.5%, p = 0.002), whereas the placebo showed no change (- 0.08%, p = 0.793). CONCLUSIONS: CoQ10 supplementation significantly reduced post-exercise cardiac stress markers (GDF-15, NT-proBNP, hs-TnT) and improved TTF in athletes. These findings suggest potential associations with reduced cardiac stress responses to exercise, but further studies are required to confirm the clinical significance and long-term effects of CoQ10 supplementation on cardiovascular health in athletes. TRIAL REGISTRATION: not applicable. © 2026. The Author(s).

BACKGROUND AND AIMS: Atrial fibrillation (AF), heart failure (HF), and undernutrition represent a complex triad with major clinical and socioeconomic consequences in older adults, often predisposing to frailty. Undernutrition often remains underdiagnosed due to a reliance on weight-based measures and limited awareness of inflammation-related cachexia. The AMBROSIA study aims to fill these gaps by exploring the response of the microbiota-inflammation-brain axis to a targeted, fortified food product-based intervention, with comprehensive outcome assessments, alongside mechanistic/exploratory -omics analyses and gut microbiota (GM) functional profiling. METHODS AND RESULTS: This single-center, prospective, parallel-group randomized controlled trial aims to enroll 120 older adults with confirmed AF and/or HF. Participants will be randomized 1:1 into an intervention group (n = 60) or control group (n = 60). All participants receive individualized dietary counseling; the intervention group additionally consumes one AMBROSIA nutritional bar daily for six months. The bar contains hydrolyzed proteins, inulin, CoQ₁₀, and probiotics (L. rhamnosus IMC 501® and L. paracasei IMC 502®) in a flavonoid-rich chocolate matrix. Clinical, cognitive, and nutritional data, along with blood, saliva, urine, and stool samples, will be collected at baseline, 3, and 6 months. The primary endpoint is the change in skeletal muscle mass, physical function and frailty, while secondary endpoints include changes in nutritional status, inflammation, GM, metabolomics, and quality of life. CONCLUSION: By integrating cutting-edge omics tools and a multidimensional nutritional strategy, AMBROSIA aims to uncover mechanisms driving undernutrition and identify biomarkers to support personalized interventions for older patients with AF and HF.

Ageing is associated with attenuated exercise responses in skeletal muscle, which may be related to a failure of muscle redox signalling. The attenuation of redox responses to exercise in aged muscle has been linked to perturbations in redox homeostasis induced by age-related increases in mitochondrial oxidative stress. Accordingly, we investigated the effects of supplementation with the mitochondria-targeted antioxidant MitoQ on mitochondrial bioenergetics and H2O2 emission as well as acute exercise-induced redox responses in skeletal muscle of older individuals. In a randomised, double-blind, placebo-controlled, parallel design, 10 males and 12 females aged 65-80 years were randomised to receive either MitoQ (20 mg/day) or a placebo for 12 weeks before completing a single bout of exercise. Vastus lateralis muscle biopsies were collected before supplementation and before, immediately post- and 4 h post-exercise. MitoQ supplementation reduced mitochondrial H2O2 emission capacity in skeletal muscle but did not impact mitochondrial respiration, H2O2 emission in the presence of ADP, or the sensitivity for ADP to stimulate respiration (apparent Km) and attenuate H2O2 emission (apparent IC50). Acute exercise-induced peroxiredoxin oxidation in skeletal muscle was not altered by MitoQ supplementation. Similarly, MitoQ had no effect on the phosphorylation of several redox-sensitive protein kinases (AMPK, p38 MAPK, and ERK1/2) or the upregulation of mitochondrial and antioxidant genes following exercise. Collectively, these findings indicate that MitoQ supplementation did not influence the basal myocellular redox state or redox responses to exercise in skeletal muscle of older individuals.

BACKGROUND: Coenzyme Q10 (CoQ10) is a mitochondrial cofactor with antioxidant and anti-inflammatory properties that may counteract mechanisms implicated in depression, such as oxidative stress and mitochondrial dysfunction. We evaluated the efficacy of CoQ10 supplementation on depressive symptoms and fatigue in patients with depression, whether as a primary disorder or in the context of underlying medical illness. METHODS: A systematic review and meta-analysis was conducted according to PRISMA guidelines. Randomized controlled trials comparing CoQ10 with placebo or standard treatment in patients diagnosed with depression were eligible, independent of concomitant medical conditions. Outcomes included changes in depressive symptoms and fatigue. Data were pooled using random-effects models, with standardized mean differences (SMD) and 95% CIs. Heterogeneity was assessed with the I 2 statistic, and sensitivity analyses were performed using a leave-one-out approach. RESULTS: Five RCTs with 474 participants were included. Three trials enrolled patients with depression associated with significant medical conditions-multiple sclerosis, breast cancer, and polycystic ovary syndrome-while 2 included patients with primary depressive disorders (major depression and bipolar disorder). CoQ10 supplementation significantly reduced depressive symptoms compared with control (SMD: -0.68; 95% CI: -1.02 to -0.33; P <0.01; I2 =58%), with consistent results across rating scales. Sensitivity analysis indicated that heterogeneity was largely driven by a single study. No significant benefit was observed for fatigue (SMD: -0.33; 95% CI: -1.38 to 0.72; P =0.54; I2 =89%), based on only 2 trials. CONCLUSIONS: CoQ10 supplementation may confer moderate improvement in depressive symptoms across diverse populations. However, the evidence for fatigue remains inconclusive.

Statins are effective drugs for lowering hypercholesterolemia and preventing cardiovascular diseases. They can cause various side effects, in particular statin-associated muscle symptoms (SAMS) associated with mitochondrial dysfunction and micronutrient depletion. The aim of this systematic review and meta-analysis was to investigate the efficacy of a supplementation with Coenzyme Q10 (CoQ10) against SAMS in statin-treated patients. A systematic literature search was performed in Medline and Cochrane Library in August 2024. Studies were selected for a meta-analysis according to the following criteria: randomised controlled trials (RCTs), adults taking statins (any type and dose), supplementation of CoQ10, a comparable control group, and muscle pain as outcome criterion. Cochrane Risk of Bias tool was used for bias assessment. Seven RCTs with 389 patients in total were included in this meta-analysis. The selected studies included 35 to 76 patients and had a duration ranging from 30 to 90 days with CoQ10 dosages ranging from 100 to 600 mg per day. Results show a significant reduction of SAMS in four trials and no significant change in three trials. Overall, a significant reduction in SAMS, measured as pain intensity, after CoQ10 supplementation was found: weighted mean difference (WMD) -0.96 (95% Confidence Interval -1.88; -0.03), p < 0.05. Supplementation of CoQ10 can reduce muscle pain in patients with SAMS, which is relevant for their well-being and treatment continuation. More research is needed for evidence-based recommendations. © The Author(s) 2025.

BACKGROUND: Coenzyme Q10 (CoQ-10) plays a vital role in cellular energy production and protection against oxidative stress. However, its absorption from orally administered forms is limited due to its poor water solubility and relatively large molecular weight. While co-ingesting CoQ-10 with a fatty meal can enhance absorption, this approach is not always practical. The aim of this study was to evaluate whether a liposomal formulation of CoQ-10 could improve its absorption compared with standard CoQ-10 without the need for the concurrent consumption of fatty foods. METHODS: In a randomized, double-blind, placebo-controlled, crossover study design, 7 men and 11 women (n = 18; age: 33.5 ± 6.4 years, height: 171.2 ± 8.1 cm, weight: 65.6 ± 8.8 kg) ingested a single dose of placebo (PLA), 100 mg of unformulated CoQ-10, or 100 mg of liposomal CoQ-10 (Lipo CoQ-10, LipoVantage®, Specnova, LLC, Tyson Corner, VA, USA). Venous blood samples were collected at 0, 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12, and 24 h after ingestion and analyzed for plasma CoQ-10 concentrations. RESULTS: CoQ-10and Lipo CoQ-10 demonstrated significantly greater Cmax and AUC0-24 compared with placebo (p < 0.001). Additionally, Lipo CoQ-10 had significantly higher Cmax (+31.3%, p < 0.001) and AUC0-24 (+22.6%, p < 0.001) values as compared with CoQ-10. CoQ-10 formulations were well-tolerated, with no significant changes in safety markers (blood pressure, renal function, liver enzymes, and lipid profile; p > 0.05), indicating a favorable safety profile. CONCLUSION: Liposomal delivery significantly enhances CoQ-10 absorption. CLINICAL TRIAL REGISTRATION: https://www.ctri.nic.in identifier CTRI/2024/04/066483.

Polycystic ovary syndrome is a complex heterogenous reproductive endocrine disorder affecting mainly reproductive age women worldwide. The syndrome primarily is associated with hyperandrogenism, hyperinsulinemia, menstrual irregularity, infertility, hormonal dysregulation and obesity. Here, we examined the effects of Acetyl-L-Carnitine, L-Arginine, CoQ10, (Carnitine + Arginine + CoQ10) and Metformin, alone and in combination, on PCOS management. The trial included 63 females diagnosed with PCOS. The participants were treated with either Carnitine + Arginine + CoQ10 alone (nutraceutical group) or in combination with metformin (combination group) for six months. The outcome measures included demographic, anthropometric, clinical, endocrine, metabolic, quality of Life and stress response of the participants. Over 24 weeks, both treatment regimens improved metabolic, hormonal, and psychological outcomes in women with PCOS. Repeated-measures ANCOVA showed significant group × time interactions for BMI (p < .001, η2 = .220), waist circumference (p < .001, η2 = .314), and hip circumference (p < .001, η2 = .428), favoring the combination group. Hormonal responses varied: DHEAS (p = .045, η2 = .082), FAI (p < .001, η2 = .223), testosterone (p = .004, η2 = .113), and prolactin (p = .032, η2 = .072) declined more in the combination group, whereas LH decreased more in the nutraceutical group (p < .001, η2 = .231). Quality of life improved significantly in both arms, with greater gains in the combination group (p = .037, η2 = .071). Oxidative stress (MDA) also declined significantly in both groups (p = .003), with larger numerical reductions in the combination arm (- 22% vs - 6%), though between-group differences were not significant (p = .329). Both nutraceutical and combination therapies led to significant improvements in metabolic, hormonal, and psychological outcomes in women with PCOS over 24 weeks. Repeated-measures ANCOVA confirmed greater reductions in BMI, waist and hip circumference, DHEAS, FAI, testosterone, and prolactin, as well as superior quality-of-life gains with combination therapy. Nutraceutical therapy exerted stronger effects on LH suppression, while oxid

www.clinicaltrials.gov identifier is NCT06743802. Plain Language Summary: This study explores whether coenzyme Q10 (CoQ10), a nutritional supplement with antioxidant and anti-inflammatory properties, can reduce pain after video-assisted thoracoscopic surgery (VATS). Postoperative pain is a frequent concern following VATS and is often managed with conventional analgesics. However, these medications may be associated with side effects and may affect recovery.CoQ10 has been suggested to improve cellular energy balance and modulate inflammation, which could contribute to pain relief. Despite this theoretical basis, its clinical effectiveness in the context of VATS has not been confirmed.The aim of this study is to evaluate whether CoQ10 can lessen postoperative pain, reduce reliance on standard analgesics, and improve recovery after surgery. If proven effective, CoQ10 may represent an adjunct or alternative strategy for postoperative pain management, with potential benefits for patient outcomes and healthcare efficiency.

INTRODUCTION: The dental community has shown interest in the potential of Omega-3 and coenzyme Q10 for reducing inflammation in the periodontium. These antioxidant agents may enhance the outcomes of non-surgical periodontal treatments. This study aimed to investigate the potential benefits of CoQ10 and Omega-3 supplements in improving periodontal health and the TAC of saliva in individuals with chronic periodontitis. METHODS: In a double-blind, randomized clinical trial, 75 individuals were diagnosed with chronic periodontitis. These individuals were randomly allocated into three groups. The periodontal examination involved a total of 300 teeth across the three groups. The periodontal parameters of the two molars adjacent to the mandible were measured using a periodontal probe. All patients underwent scaling and root planing. Groups A and B received CoQ10 and Omega-3 respectively, while Group C served as the control. The TAC of the non-stimulated saliva samples was evaluated to assess any changes before and after 2 months. Statistical techniques were employed to compare the CAL index and PPD between the groups under study. RESULTS: The analysis of the gingival index indicated a notable reduction in inflammation within the Omega-3 group compared to both the CoQ10 and control groups, with a nearly 30% decrease observed. Furthermore, the bleeding on probing index within the Omega-3 group demonstrated significant improvements when contrasted with the CoQ10 and control groups, with this decrease being statistically significant. Additionally, the levels of TAC in the patients' saliva across all three groups exhibited changes when compared to the initial measurements. CONCLUSION: These findings provide valuable insights into the potential therapeutic effects of Omega-3 and CoQ10 supplementation on periodontal health and the antioxidant capacity of saliva. © 2024 THE AUTHORS.